Cirugía y Cirujanos

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Cirugía y Cirujanos >Year 2007, Issue 6

Robledo-Ogazón F, Lizaola-Pérez B, Mier-Giraud F, Bojalil-Durán L
Abdominal wall infection due to mucormycosis. Case report
Cir Cir 2007; 75 (6)

Language: Español
References: 27
Page: 465-469
PDF: 134.30 Kb.

[Full text - PDF]


Zygomycosis are infections due to fungus from the Zygomycetes family, and one of them is Mucor. They are a rare opportunist species that may cause severe invasive and often fatal infections. This infection has a special predilection for diabetic patients, transplant patients and those undergoing intensive cancer therapies, as well as other patients with an immunocompromised condition. Rapid diagnosis and opportune and current treatment is the key for patient surveillance. The most frequent site of this infection is the upper respiratory tract due to spore transport by air, although there are other sites in which these organisms can produce infection such as soft tissue of the abdominal wall. In this study, we present an abdominal wall infection by Mucor and describe its medical and surgical treatment.

Key words: Zygomycosis, mucormycosis, abdominal wall infection.


  1. 1. Brown J. Zygomycosis: an emerging fungal infection. Am J Health Syst Pharm 2005;62:2593-2596.

  2. 2. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000;13:236-301.

  3. 3. Hejny C, Kerrison JB, Newman NJ, Stone CM. Rhino-orbital mucormycosis in a patient with acquired immunodeficiency syndrome (AIDS) and neutropenia. Am J Ophthalmol 2001;132:111-112.

  4. 4. Sánchez MR, Ponge-Wilson I, Moy JA, Rosenthal S. Zygomycosis and HIV infection. J Am Acad Dermatol 1994;30:904-908.

  5. 5. Belin L. Sawmill alveolitis in Sweden. Int Arch Allergy Appl Immunol 1987;82:440-443.

  6. 6. Song WK, Park HJ, Cinn YW, et al. Primary cutaneous mucormycosis in a trauma patient. J Dermatol 1999;26:825-828.

  7. 7. Paparello SF, Parry RL, MacGillivray DC, Brock N, Mayers DL. Hospital-acquired wound mucormycosis. Clin Infect Dis 1992;14:350-352.

  8. 8. Carr EJ, Scott P, Gradon JD. Fatal gastrointestinal mucormycosis that invaded the postoperative abdominal wall wound in an immunocompetent host. Clin Infect Dis 1999;29:956-957.

  9. 9. Newton WD, Cramer FS, Norwood SH. Necrotizing fasciitis from invasive Phycomycetes. Crit Care Med 1987;15:331-332.

  10. 10. Lakshmi V, Rani TS, Sharma S, et al. Zygomycotic necrotizing fasciitis caused by Apophysomyces elegans. J Clin Microbiol 1993;31:1368-1369.

  11. 11. González CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am 2002;16:895-914.

  12. 12. Marchevsky AM, Bottone EJ, Geller SA, et al. The changing spectrum of disease: etiology and diagnosis of mucormycosis. Hum Pathol 1980; 11:457-64.

  13. 13. Tedder M, Spratt JA, Anstadt MP, et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994;57:1044-1050.

  14. 14. Parfrey NA. Improved diagnosis and prognosis of mucormycosis: a clinicopathologic study of 33 cases. Medicine (Baltimore) 1986;65:113-123.

  15. 15. Artis WM, Fountain JA., Delcher HK, Jones HE. A mechanism for suceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982 ; 31:1109-1114.

  16. 16. Gómez-López A, Cuenca-Estrella M, Monzón A, Rodríguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole and voriconazole. J Antimicrob Chemother 2001;48:919-921.

  17. 17. Larkin JA, Montero J. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003;20:201-206.

  18. 18. Dannaoui E, Afeltra J, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002;46:2708-2711.

  19. 19. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396.

  20. 20. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002;46:1581-1582.

  21. 21. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002;46:2310-2312.

  22. 22. Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis 1994;19:67-76.

  23. 23. Price JC, Stevens DL. Hyperbaric oxygen in the treatment of rhinocerebral mucormycosis. Laryngoscope 1980;90:737-747.

  24. 24. Bentur Y, Shupak A, Ramon Y, et al. Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus. Plast Reconstr Surg 1998;102:822-824.

  25. 25. Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988;10:551-559.

  26. 26. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997;175:1012-1015.

  27. 27. Brummer E, Maqbool A, Stevens DA. Protection of bronchoalveolar macrophages by granulocyte-macrophage colony-stimulating factor against dexamethasone suppression of fungicidal activity for Aspergillus fumigatus conidia. Med Mycol 2001;39:509-515.

>Journals >Cirugía y Cirujanos >Year 2007, Issue 6

· Journal Index 
· Links 
Copyright 2010